A. Stewart

发表

Differential Expression of Cytokine Genes in Fibroblasts Derived from Skin Biopsies of Patients who Developed Minimal or Severe Normal Tissue Damage after Radiotherapy

C. West, S. Quarmby, B. Magee, 2002, Radiation research.

Axillary recurrence following conservative surgery and radiotherapy in early breast cancer.

J. Livsey, R. Swindell, B. Magee, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients

A. Hajeer, C. West, Shant Kumar, 2003, International journal of radiation biology.

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

W. Sauerbrei, R. Blamey, M. Schumacher, 2003, Osteoporosis International.

Plasma TGFβ1 during pelvic radiotherapy for gynaecological malignancy

R. Dale, B. Jones, C. Pusey, 2006, Acta oncologica.

Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer

Shant Kumar, N. Bundred, Chenggang Li, 2000, International journal of cancer.

Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein.

D. Hedley, V. Vukovic, A. Stewart, 2000, International journal of radiation biology.

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).

A. Stewart, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.

A. Curnow, N. Dobbs, C. Twelves, 1994, British Journal of Cancer.

TGF‐β1 levels in pre‐treatment plasma identify breast cancer patients at risk of developing post‐radiotherapy fibrosis

S. Kumar, Shant Kumar, Chenggang Li, 1999, International journal of cancer.

Aetiology and prevention of emesis induced by radiotherapy

P. Feyer, A. Stewart, O. Titlbach, 1998, Supportive Care in Cancer.

Adjuvant radiotherapy for breast cancer - do we need new techniques?

R. Swindell, B. Magee, A. Stewart, 2001 .

Efficacy of an Ondansetron Orally Disintegrating Tablet: A Novel Oral Formulation of this 5-HT3 Receptor Antagonist in the Treatment of Fractionated Radiotherapy-Induced Nausea and Emesis

L. Goedhals, L. Souhami, P. Feyer, 1999 .

Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study

P. Lønning, L. Fallowfield, L. Gibson, 2003, BMJ : British Medical Journal.

Optimal selection of antiemetics in children receiving cancer chemotherapy

M. Aapro, F. Roila, A. Stewart, 1998, Supportive Care in Cancer.

Changes in spontaneous SCE frequencies as a function of sampling time in lymphocytes from normal donors and cancer patients.

D. Scott, A. Stewart, D. Parkes, 1985, Mutation research.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

J. Cuzick, W. Sauerbrei, R. Blamey, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

J. Yarnold, J. Haviland, J. Bliss, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vascular endothelial growth factor-C in patients with breast cancer.

C. Kirwan, Shant Kumar, Chenggang Li, 2007, In vivo.

Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study

J. Forster, L. Goedhals, X. Froger, 1995 .

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.

D. Kerr, T. Powles, G. Rustin, 1992, Oncology.

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.

L. Goedhals, X. Froger, A. Gudgeon, 1995, Oncology.

Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

J. Verweij, D. Cunningham, J. Smyth, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients.

C. West, J. Dickson, B. Magee, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Rapid onset of acute myeloid leukaemia following radiotherapy and chemotherapy for metastatic seminoma of the testis

P. Wilkinson, A. Stewart, 2004, Journal of Cancer Research and Clinical Oncology.

Local recurrence of breast cancer following surgery and radiotherapy: incidence and outcome.

C. Mcbain, R. Swindell, B. Magee, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.

L. Goedhals, L. Souhami, P. Feyer, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy

A. Kiltie, A. Stewart, A. Sykes, 1997, Supportive Care in Cancer.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Joanne S Haviland, John R Yarnold, J. Yarnold, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Inter-fraction motion and dosimetric consequences during breast intensity-modulated radiotherapy (IMRT).

Christopher Moore, T. Marchant, C. Moore, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Outcome of radiotherapy after breast conserving surgery in screen detected breast cancers.

R. Swindell, B. Magee, A. Stewart, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy

S. B. Lucas, P. Wilkinson, J. Margison, 2004, Cancer Chemotherapy and Pharmacology.

Primary malignant lymphoma of the thyroid: a clinicopathological analysis.

J. Logue, S. Banerjee, A. Stewart, 1992, International journal of radiation oncology, biology, physics.

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

A. Howell, W. Ryder, P. Wilkinson, 2004, British Journal of Cancer.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .